Autoantibody profiling of patients with antiphospholipid syndrome using an automated multiplexed immunoassay system

Autoimmunity Reviews

Volumn 13, Issue 1, 2014, Pages 59-63

  Tozzoli, R ^a   Villalta, D ^a  

^a S MARIA DEGLI ANGELI HOSPITAL   (Italy)

Author keywords

Anti 2glycoprotein I; Anticardiolipin; Antiphospholipid syndrome; Multiplex immunoassay

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; AUTOANALYSIS; AUTOANALYZER; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; IMMUNOASSAY; LABORATORY DIAGNOSIS; MALE; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY AND SPECIFICITY;

ANTI-Β2GLYCOPROTEIN I; ANTICARDIOLIPIN; ANTIPHOSPHOLIPID SYNDROME; MULTIPLEX IMMUNOASSAY;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; AUTOMATION; HUMANS; IMMUNOASSAY; REPRODUCIBILITY OF RESULTS;

EID: 84886946488     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.08.007     Document Type: Review

References (36)

1. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006, 4:295-306.
2. Devreese K., Hoylaerts M.F. Challenges in the diagnosis of antiphospholipid syndrome. Clin Chem 2010, 56:930-940.
3. Favaloro E.J. Variability and diagnostic utility of antiphospholipid antibodies including lupus anticoagulants. Int J Lab Hematol 2013, 35:269-274.
4. Galli M., Reber G., de Moerloose P., de Groot P.G. Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemost 2008, 6:399-401.
5. Pengo V., Banzato A., Denas G., Padayattil Jose S., Bison E., Hoxha A., et al. Correct laboratory approach to APS diagnosis and monitoring. Autoimmun Rev 2013, 12:832-834.
6. Cervera R., Conti F., Doria A., Iaccarino L., Valesini G. Does sieronegative antiphospholipid syndrome really exist?. Autoimmun Rev 2012, 11:581-584.
7. Mahler M., Norman G.L., Meroni P.L., Khamashta M. Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev 2012, 12:313-317.
8. Capozzi A., Lococo E., Grasso M., Longo A., Garofalo T., Misasi R., et al. Detection of antiphospholipid antibodies by automated chemiluminescence assay. J Immunol Methods 2012, 379:48-52.
9. Persijn L., Decavele A.-S., Schouvers S., Devreese K. Evaluation of a new set of automated chemiluminescence assays for anticardiolipin and anti-beta2b glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. Thromb Res 2011, 128:565-569.
10. Roggenbuck D., Egerer K., von Landerberg P., Hiemann R., Feist E., Burmester G.-R., et al. Antiphospholipid antibody profiling: time for a new technical approach?. Autoimmun Rev 2012, 11:821-826.
11. Pietrangeli S.S., Favaloro E.J., Harris E.N., Meroni P.L., Tincani A., Wong R.C., et al. Standards and reference materials for the anticardiolipin and anti-beta(2)glycoprotein I assays: a report of the recommendations from the APL Task Force at the 13th International Congress on Antiphospholipid antibodies. Clin Chim Acta 2012, 413:358-360.
12. De Groot P.G., Urbanus R.T. The future of antiphospholipid antibody testing. Semin Thromb Hemost 2012, 38:412-420.
13. Menegatti E., Berardi D., Messina M., Ferrante I., Giachino O., Spagnolo B., et al. Lab-on-a-chip: emerging analytical platforms for immune-mediated diseases. Autoimmun Rev 2013, 12:814-820.
14. Lea P., Keystone E., Mudumba S., Kahama A., Ding S.-F., Hansen J., et al. Advantages of multiplex proteomics in clinical immunology. Clin Rev Allergy Immunol 2011, 41:20-35.
15. Tozzoli R. Recent advances in diagnostic technologies and their impact in autoimmune diseases. Autoimmun Rev 2007, 6:334-340.
16. Tozzoli R., Bonaguri C., Melegari A., Antico A., Bassetti D., Bizzaro N. Current state of diagnostic technologies in the autoimmunology laboratory. Clin Chem Lab Med 2013, 51:129-138.
17. Rouquette A.-M., Desgruelles C., Laroche P. Evaluation of the new multiplexed immunoassay, FIDIS, for simultaneous quantitative determination of antinuclear antibodies and comparison with conventional methods. Am J Clin Pathol 2003, 120:676-681.
18. Tozzoli R., Villalta D., Kodermaz G., Bagnasco M., Tonutti E., Bizzaro N. Autoantibody profiling of patients with autoimmune thyroid disease using a new multiplexed immunoassay method. Clin Chem Lab Med 2006, 44:837-842.
19. Damoiseaux J., Vaessen M., Knapen Y., Csernok E., Stageman C.A., van Paasen P., et al. Evaluation of the FIDIS vasculitis multiplex immunoassay for diagnosis and follow-up of ANCA-associated vasculitis and Goodpasture's disease. Ann N Y Acad Sci 2007, 1109:464-472.
20. Tozzoli R., Barzilai O., Ram M., Villalta D., Bizzaro N., Sherer Y., et al. Infections and autoimmune thyroid diseases: parallel detection of aAbs against pathogens with protomic technology. Autoimmun Rev 2008, 8:112-115.
21. Shovman O., Gilburd B., Barzilai O., Shinar E., Larisa B., Zandman-Goddard G., et al. Evaluation of the BioPlex 2200 ANA screen: analysis of 510 healthy subjects: incidence of natural/predictive aAbs. Ann N Y Acad Sci 2005, 1050:380-388.
22. Moder K.G., Wener M.H., Weisman M.H., Ishimori M.L., Wallace D.J., Buckeridge D.L., et al. Measurement of antinuclear antibodies by multiplex immunoassay: a prospective, multicenter clinical evaluation. J Rheumatol 2007, 34:978-986.
23. Desplat-Jego S., Bardin N., Larida B., Sanmarco G. Evaluation of the BioPlex 2200 ANA screen for the detection of antinuclear antibodies and comparison with conventional methods. Ann N Y Acad Sci 2007, 1109:245-255.
24. Kaul R., Johnson K., Scholz H., Marr G. Performance of the BioPlex™ 2200 autoimmune vasculitis kit. Autoimmun Rev 2009, 8:224-227.
25. Bardin N., Desplat-Jego S., Daniel L., Jourde Chiche N., Sanmarco M. BioPlex multiplexed system: simultaneous detection of anti-dsDNA and anti-chromatin antibodies in patients with systemic lupus erythematosus. Autoimmunity 2009, 42:63-68.
26. Hanly J.G., Thompson K., McCurdy G., Fougere L., Theriault C., Wilton K. Measurement of aAbs using multiplex technology in patients with systemic lupus erythematosus. J Immunol Methods 2010, 352:147-152.
27. Shanmugam V.K., Swistowski D.R., Saddic N., Wang H., Steen V.D. Comparison of immunofluorescence and multiplex antinuclear antibody screening in systemis sclerosis. Clin Rheumatol 2011, 30:1363-1368.
28. Kim Y., Park Y., Lee E.Y., Kim H.S. Comparison of automated multiplexed bead-based ANA screening assay with ELISA for detecting five common anti-extractable nuclear antigens and anti-dsDNA in systemic rheumatic diseases. Clin Chim Acta 2012, 413:308-311.
29. Op De Beéck K., Vermeesch P., Verscheueren P., Westhovens R., Marien G., Blockmans D., et al. Antinuclear antibody detection by automated multiplex immunoassay in untreated patients at the time of diagnosis. Autoimmun Rev 2012, 12:137-143.
30. Bose N., Wang X., Gupta M., Yao Q. The clinical utility of anti-chromatin antibodies as measured by BioPlex 2200 in the diagnosis of systemic lupus erythematosu versus other rheumatic diseases. Int J Clin Exp Med 2012, 5:316-320.
31. Bruner B.F., Guthridge J.M., Lu R., Vidal G., Kelly J.A., Robertson J.M., et al. Comparison of autoantibody specificities between traditional and bead-based assays in a large, diverse collection of patients with systemic lupus erythematosus and family members. Arthritis Rheum 2012, 64:3677-3686.
32. Venner A.A., Ibanez D., Gladman D.D., Urowitz M.B., MacKinnon A., Blasutig I.M., et al. Comparison of three anti-dsDNA assays: performance and correlation with systemic lupus erythematosus disease activity. Clin Biochem 2013, 46:317-320.
33. Favaloro E.J., Wong R.C.W., Silvestrini R., McEvoj R., Jovanovich S., Roberts-Thomson Pl Multilaboratoty peer assessment quality assurance program-based evaluation for anticardiolipin antibody, and beta2-glycoprotein I antibody testing. Semin Thromb Hemost 2005, 31:73-84.
34. Pengo V., Biasiolo A., Bison E., Chantarangkul V., Tripodi A. Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-β2-glycoprotein I activity. Thromb Res 2007, 120:127-133.
35. Villalta D., Alessio M.G., Tampoia M., Da Re A., Stella S., Tozzoli R., et al. Accuracy of the first fully automated method for anti-cardiolipin and anti-β2 glycoprotein I antibody detection for the diagnosis of antiphospholipid syndrome. Ann N Y Acad Sci 2009, 1173:21-27.
36. Meijide H., Sciascia S., Sanna G., Khamashta M.A., Bertolaccini M.L. The clinical relevance of IgA anticardiolipin and IgA anti-β2glycoprotein I antiphospholipid antibodies. A systematic review. Autoimmun Rev 2013, 12:421-425.